Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies (Q34563378)

3 August 2017

1 reference

title

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies (English)

1 reference

3 August 2017

1 reference

Leontien C M Kremer

1 reference

3 August 2017

Karlijn A Wouters

1 reference

3 August 2017

Tracie L Miller

series ordinal

1 reference

3 August 2017

Eugene H Herman

series ordinal

1 reference

3 August 2017

Steven E Lipshultz

series ordinal

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

British Journal of Haematology

3 August 2017

published in

1 reference

3 August 2017

volume

131

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

561-578

1 reference

Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Mechanism of Action of Beta-Blocking Agents in Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Carvedilol as therapy in pediatric heart failure: an initial multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Protection of Normal Tissue from the Cytotoxic Effects of Chemotherapy and Radiation by Amifostine: Clinical Experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Vitamin A inhibits doxorubicin-induced membrane lipid peroxidation in rat tissues in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Vitamin A and glutathione-mediated free radical damage: competing reactions with polyunsaturated fatty acids and vitamin C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Maintenance of myocardial levels of vitamin A in heart failure due to adriamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Amifostine protection against doxorubicin cardiotoxicity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Oxygen free radicals and myocardial damage: protective role of thiol-containing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Survival of cancer patients on therapy with coenzyme Q10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Reactive oxygen species and antioxidant vitamins: mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Anthracycline-induced cardiotoxicity in children and young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Trace element risk assessment: essentiality vs. toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

A placebo-controlled study of growth hormone in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Probucol as an antioxidant and antiatherogenic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Time-Dependent and Tissue-Specific Accumulation of mtDNA and Respiratory Chain Defects in Chronic Doxorubicin Cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Does anthracycline administration by infusion in children affect late cardiotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Antioxidant nutrients and adriamycin toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Basic mechanisms in heart failure: the cytokine hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Reduction in Fas/APO-1 plasma concentrations correlates with improvement in left ventricular function in patients with idiopathic dilated cardiomyopathy treated with pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Anti-atherogenic antioxidants regulate the expression and function of proteasome alpha-type subunits in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Probucol: pharmacology and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Childhood cancer survival in Europe and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05759.X

10.1111/J.1365-2141.2005.05759.X

21 January 2018

Identifiers

DOI

1 reference

release_egvkk4ckurdxng2h773rekc3sq

3 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/egvkk4ckurdxng2h773rekc3sq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference